Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats

Journal of Steroid Biochemistry and Molecular Biology

Volumn 134, Issue 1, 2013, Pages 80-91

  Hara, Takahito ^a   Kouno, Jin ^a   Kaku, Tomohiro ^a   Takeuchi, Toshiyuki ^a   Kusaka, Masami ^a   Tasaka, Akihiro ^a   Yamaoka, Masuo ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

17,20 Lyase; Adrenal glands; Orteronel; Prostate cancer; Rat; Testes

Indexed keywords

ABIRATERONE; ALDOSTERONE; ANDROSTENEDIONE; CHORIONIC GONADOTROPIN; CORTICOSTERONE; KETOCONAZOLE; ORTERONEL; STEROID 11BETA MONOOXYGENASE; STEROID 17ALPHA MONOOXYGENASE; TESTOSTERONE;

ADRENAL CELL; ADRENAL CORTEX TUMOR; ALDOSTERONE BLOOD LEVEL; ANDROGEN SYNTHESIS; ANDROSTENEDIONE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG EFFECT; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME SPECIFICITY; IC 50; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROSTATE; RAT; SEMINAL VESICLE; SINGLE DRUG DOSE; STEROIDOGENESIS; TESTIS CELL; TESTOSTERONE BLOOD LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR CELL LINE;

ADRENAL GLANDS; ANDROGENS; ANIMALS; IMIDAZOLES; MALE; NAPHTHALENES; ORGAN SIZE; PROSTATIC NEOPLASMS; RATS; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; STEROIDS; TESTIS;

RATTUS;

EID: 84870366365     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2012.10.020     Document Type: Article

References (32)

1. M.K. Akhtar, S.L. Kelly, and M.A. Kaderbhai Cytochrome b(5) modulation of 17{alpha} hydroxylase and 17-20 lyase (CYP17) activities in steroidogenesis Journal of Endocrinology 187 2005 267 274 (Pubitemid 41685186)
2. S. Nakajin, and P.F. Hall Microsomal cytochrome P-450 from neonatal pig testis. Purification and properties of a C21 steroid side-chain cleavage system (17 alpha-hydroxylase-C17,20 lyase) Journal of Biological Chemistry 256 1981 3871 3876
3. S. Nakajin, P.F. Hall, and M. Onoda Testicular microsomal cytochrome P-450 for C21 steroid side chain cleavage. Spectral and binding studies Journal of Biological Chemistry 256 1981 6134 6139
4. G. Majdic, P.T. Saunders, and K.J. Teerds Immunoexpression of the steroidogenic enzymes 3-beta hydroxysteroid dehydrogenase and 17 alpha-hydroxylase, C17,20 lyase and the receptor for luteinizing hormone (LH) in the fetal rat testis suggests that the onset of Leydig cell steroid production is independent of LH action Biology of Reproduction 58 1998 520 525 (Pubitemid 28099119)
5. J.D. Debes, and D.J. Tindall Mechanisms of androgen-refractory prostate cancer New England Journal of Medicine 351 2004 1488 1490 (Pubitemid 39315314)
6. C.A. Heinlein, and C. Chang Androgen receptor in prostate cancer Endocrine Reviews 25 2004 276 308 (Pubitemid 38501396)
7. G. Corona, E. Baldi, and M. Maggi Androgen regulation of prostate cancer: where are we now? Journal of Endocrinological Investigation 34 2011 232 243
8. F. Labrie Endocrine therapy of prostate cancer: optimal form and timing Journal of Clinical Endocrinology and Metabolism 80 1995 1066 1071
9. T. Hara, K. Nakamura, H. Araki, M. Kusaka, and M. Yamaoka Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline Cancer Research 63 2003 5622 5628 (Pubitemid 37139887)
10. E.A. Mostaghel, S.T. Page, D.W. Lin, L. Fazli, I.M. Coleman, L.D. True, B. Knudsen, D.L. Hess, C.C. Nelson, A.M. Matsumoto, W.J. Bremner, M.E. Gleave, and P.S. Nelson Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer Cancer Research 67 2007 5033 5041 (Pubitemid 46910214)
11. E.A. Mostaghel, and P.S. Nelson Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications Best Practice and Research: Clinical Endocrinology and Metabolism 22 2008 243 258 (Pubitemid 351611949)
12. M. Yamaoka, T. Hara, and M. Kusaka Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer Clinical Cancer Research 16 2010 4319 4324
13. J.S. de Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K.N. Chi, R.J. Jones, O.B. Goodman Jr., F. Saad, J.N. Staffurth, P. Mainwaring, S. Harland, T.W. Flaig, T.E. Hutson, T. Cheng, H. Patterson, J.D. Hainsworth, C.J. Ryan, C.N. Sternberg, S.L. Ellard, A. Flechon, M. Saleh, M. Scholz, E. Efstathiou, A. Zivi, D. Bianchini, Y. Loriot, N. Chieffo, T. Kheoh, C.M. Haqq, and H.I. Scher Abiraterone and increased survival in metastatic prostate cancer New England Journal of Medicine 364 2011 1995 2005
14. S.K. Pal, and O. Sartor Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer Maturitas 68 2011 103 105
15. D.B. Agus, W.M. Stadler, D. Shevrin, L. Hart, G.R. MacVicar, O. Hamid, J.D. Hainsworth, M. Gross, J. Wang, I. Webb, D. MacLean, and R. Dreicer Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistan prostate cancer: update data from a phase 1/2 study Malaysian urological conference - Asia pacific society of uro-oncology conference poster presentation 2011
16. M. Gross, D. Shevrin, R. Dreicer, W.L. Trepicchio, D. MacLean, I. Webb, J. Wang, and D.B. Agus Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-Lyase inhibitor, in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: safety, efficacy, and evaluation of circulating tumor cells (ctcs) European multidisciplinary meeting on urological cancers oral presentation 2011
17. D.J. George, P.G. Corn, M.D. Michaelson, H.J. Hammers, J.J. Alumkal, C.J. Ryan, J.Y. Bruce, S. Moran, S.Y. Lee, P. Mortimer, and M. Hussain Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): updated results of a phase II study ASCO Meeting Abstracts 30 2012 4549
18. D.P. Petrylak, J.G. Gandhi, W.R. Clark, E.I. Heath, J. Lin, W.K. Oh, D.B. Agus, O. Kucuk, S. Moran, J. Wang, M. Bargfrede, and G. Liu Phase I results from a phase I/II study of orteronel, an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC) ASCO Meeting Abstracts 30 2012 4656
19. R. Dreicer, D.B. Agus, J. Bellmunt, J.S. De Bono, D.P. Petrylak, B. Tejura, Y. Shi, and K. Fizazi A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy ASCO Meeting Abstracts 30 2012 TPS4693
20. F. Saad, H. Akaza, M.A. Eisenberger, J. Nelson, H.I. Scher, K. Suzuki, M. Wirth, I.J. Webb, J. Wang, D. MacLean, and R. De Wit A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) ASCO Meeting Abstracts 29 2011 TPS184
21. T. Kaku, T. Hitaka, A. Ojida, N. Matsunaga, M. Adachi, T. Tanaka, T. Hara, M. Yamaoka, M. Kusaka, T. Okuda, S. Asahi, S. Furuya, and A. Tasaka Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer Bioorganic and Medicinal Chemistry 19 2011 6383 6399
22. G.A. Potter, S.E. Barrie, M. Jarman, and M.G. Rowlands Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer Journal of Medicinal Chemistry 38 1995 2463 2471
23. J. Li, Y. Li, C. Son, and A.M. Brodie Inhibition of androgen synthesis by 22-hydroximino-23,24-bisnor-4-cholen-3-one Prostate 26 1995 140 150
24. B.D. Albertson, D.D. Brandon, G.P. Chrousos, and D.L. Loriaux Adrenal 11-hydroxylase activity in a hypercortisolemic New World primate: adaptive intra-adrenal changes Steroids 49 1987 497 505
25. M. Yamaoka, T. Hara, T. Hitaka, T. Kaku, T. Takeuchi, J. Takahashi, S. Asahi, H. Miki, A. Tasaka, and M. Kusaka Orteronel A novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys Journal of Steroid Biochemistry and Molecular Biology 129 2012 115 128
26. C. Mahler, J. Verhelst, and L. Denis Ketoconazole and liarozole in the treatment of advanced prostatic cancer Cancer 71 1993 1068 1073 (Pubitemid 23049633)
27. S. Haidar, P.B. Ehmer, S. Barassin, C. Batzl-Hartmann, and R.W. Hartmann Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo Journal of Steroid Biochemistry and Molecular Biology 84 2003 555 562 (Pubitemid 36588809)
28. M.G. Rowlands, S.E. Barrie, F. Chan, J. Houghton, M. Jarman, R. McCague, and G.A. Potter Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis Journal of Medicinal Chemistry 38 1995 4191 4197
29. M. Jarman, S.E. Barrie, and J.M. Llera The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors Journal of Medicinal Chemistry 41 1998 5375 5381 (Pubitemid 29031321)
30. W.M. van Weerden, H.G. Bierings, G.J. van Steenbrugge, F.H. de Jong, and F.H. Schroder Adrenal glands of mouse and rat do not synthesize androgens Life Sciences 50 1992 857 861
31. T. Hara, H. Miyazaki, A. Lee, C.P. Tran, and R.E. Reiter Androgen receptor and invasion in prostate cancer Cancer Research 68 2008 1128 1135 (Pubitemid 351272231)
32. R.B. Montgomery, E.A. Mostaghel, R. Vessella, D.L. Hess, T.F. Kalhorn, C.S. Higano, L.D. True, and P.S. Nelson Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Research 68 2008 4447 4454